Lyell Immunopharma Current Assets

Lyell Immunopharma (LYEL) currently reports a current assets of $210M as of June 2026. That compares with $280M in the prior-year period — down 24.3% year over year. Use the charts on this page to explore Lyell Immunopharma's current assets history and peer comparisons.

Lyell Immunopharma's current assets decreased from $280M to $210M — a 24.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lyell Immunopharma reported $210M in current assets as of June 2026. That compares with $280M in the prior-year period — down 24.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lyell Immunopharma, and consider following LYEL for alerts when major investors trade the stock.

Lyell Immunopharma is classified in the Healthcare sector. On current assets, it currently shows $210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYEL with unrelated industries.